Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free MLAB Stock Alerts

Mesa Laboratories (MLAB) Financials

Mesa Laboratories logo
$105.54 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$105.43 -0.11 (-0.10%)
As of 07/2/2026 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Mesa Laboratories

Annual Income Statements for Mesa Laboratories

This table shows Mesa Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 114 118 -2.96 7.48 1.78 3.27 1.87 0.93 -254 -1.97 6.71
Consolidated Net Income / (Loss)		 11 11 -2.96 7.48 1.78 3.27 1.87 0.93 -254 -1.97 6.71
Net Income / (Loss) Continuing Operations		 114 118 -2.96 7.48 1.78 3.27 1.87 0.93 -254 -1.97 6.71
Total Pre-Tax Income 		16 14 0.30 8.62 3.86 2.30 3.57 -0.39 -276 5.96 12
Total Operating Income		 16 16 2.18 9.78 7.92 12 4.70 3.32 -272 16 19
Total Gross Profit		 103 106 55 61 65 87 109 134 133 151 158
Total Revenue		 169 187 96 103 118 134 184 219 216 241 249
Operating Revenue		 169 0.00 96 103 118 134 184 219 216 241 249
Total Cost of Revenue		 66 81 42 42 52 47 75 85 83 90 91
Operating Cost of Revenue		 66 81 42 42 52 47 75 85 83 90 91
Total Operating Expenses		 -16 -16 52 51 57 75 104 130 405 135 140
Selling, General & Admin Expense		 31 33 35 40 51 64 89 110 111 115 119
Research & Development Expense		 3.97 4.16 3.54 3.51 6.36 10 16 20 19 20 20
Impairment Charge		 0.00 0.00 14 4.77 - - 0.00 0.00 275 0.00 0.00
Total Other Income / (Expense), net		 -0.77 -2.02 -1.88 -1.16 -4.06 -10 -1.13 -3.71 -3.57 -10 -6.50
Interest Expense		 - - 1.85 1.75 5.50 8.02 3.89 4.77 5.70 8.97 11
Other Income / (Expense), net		 -0.77 -2.02 -0.03 0.56 1.44 -2.03 2.76 1.06 2.12 -1.40 4.20
Income Tax Expense		 4.39 3.11 3.26 1.14 2.08 -0.97 1.70 -1.32 -21 7.94 5.30
Basic Earnings per Share		 $3.10 $3.04 ($0.79) $1.95 $0.42 $0.66 $0.36 $0.17 ($47.20) ($0.36) $1.22
Weighted Average Basic Shares Outstanding		 3.61M 3.68M 3.77M 3.84M 4.20M 4.98M 5.21M 5.32M 5.39M 5.42M 5.51M
Diluted Earnings per Share		 $2.97 $2.91 ($0.79) $1.86 $0.41 $0.64 $0.35 $0.17 ($47.20) ($0.36) $1.21
Weighted Average Diluted Shares Outstanding		 3.76M 3.84M 3.77M 4.03M 4.37M 5.12M 5.34M 5.36M 5.39M 5.42M 5.57M
Weighted Average Basic & Diluted Shares Outstanding		 3.60M 3.70M 3.70M 3.90M 4.39M 5.14M 5.27M 5.37M 5.41M 5.46M 5.52M
Cash Dividends to Common per Share		 - - - $0.64 $0.64 $0.64 $0.64 $0.64 $0.64 $0.64 $0.64

Quarterly Income Statements for Mesa Laboratories

This table shows Mesa Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2025 12/31/2025 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 1.31 0.45 0.61 -0.55 -1.23 2.12 -255 3.39 2.48 3.63 -12
Consolidated Net Income / (Loss)		 1.31 0.45 0.61 -0.55 -1.23 2.12 -255 3.39 2.48 3.63 -12
Net Income / (Loss) Continuing Operations		 1.31 0.45 0.61 -0.55 -1.23 2.12 -255 3.39 2.48 3.63 -12
Total Pre-Tax Income 		3.38 1.92 -0.28 -0.94 -1.33 1.95 -275 3.91 2.00 4.60 -6.35
Total Operating Income		 4.00 3.40 0.52 -0.66 -0.06 -0.07 -271 5.58 4.72 7.98 -0.73
Total Gross Profit		 36 33 33 31 32 33 37 37 37 42 36
Total Revenue		 59 54 56 51 53 53 59 58 61 65 60
Operating Revenue		 59 54 56 51 53 53 59 58 61 65 60
Total Cost of Revenue		 22 22 22 19 21 20 22 21 23 23 23
Operating Cost of Revenue		 22 22 22 19 21 20 22 21 23 23 23
Total Operating Expenses		 32 29 33 32 32 33 308 32 33 34 37
Selling, General & Admin Expense		 27 25 28 27 27 29 28 27 28 29 32
Research & Development Expense		 4.99 4.80 5.00 4.81 4.99 4.29 5.20 4.74 5.05 5.03 5.12
Total Other Income / (Expense), net		 -0.61 -1.49 -0.79 -0.27 -1.27 2.01 -4.05 -1.68 -2.73 -3.38 -5.63
Interest Expense		 1.21 1.16 1.38 1.05 0.91 1.86 1.89 -0.05 2.86 3.04 2.96
Other Income / (Expense), net		 0.60 -0.32 0.59 0.78 -0.36 3.87 -2.16 -1.72 0.14 -0.34 -2.66
Income Tax Expense		 2.08 1.47 -0.89 -0.39 -0.10 -0.17 -21 0.52 -0.48 0.97 6.07
Basic Earnings per Share		 $0.25 $0.08 $0.11 ($0.10) ($0.23) $0.39 ($47.26) $0.63 $0.45 $0.66 ($2.28)
Weighted Average Basic Shares Outstanding		 5.32M 5.34M 5.32M 5.37M 5.39M 5.39M 5.39M 5.40M 5.51M 5.53M 5.42M
Diluted Earnings per Share		 $0.24 $0.08 $0.12 ($0.10) ($0.23) $0.39 ($47.26) $0.62 $0.45 $0.65 ($2.26)
Weighted Average Diluted Shares Outstanding		 5.36M 5.36M 5.36M 5.37M 5.39M 5.40M 5.39M 5.42M 5.54M 5.57M 5.42M
Weighted Average Basic & Diluted Shares Outstanding		 5.34M 5.35M 5.37M 5.38M 5.39M 5.39M 5.41M 5.50M 5.52M 5.52M 5.46M

Annual Cash Flow Statements for Mesa Laboratories

This table details how cash moves in and out of Mesa Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 3.66 0.13 -0.35 4.72 71 182 -215 -16 -27 -21 -18
Net Cash From Operating Activities		 17 17 26 31 27 37 39 28 44 47 43
Net Cash From Continuing Operating Activities		 17 17 26 31 27 37 39 28 22 28 25
Net Income / (Loss) Continuing Operations		 11 11 -2.96 7.48 1.78 3.27 1.87 0.93 -254 -1.97 6.71
Consolidated Net Income / (Loss)		 11 11 -2.96 7.48 1.78 3.27 1.87 0.93 -254 -1.97 6.71
Depreciation Expense		 7.17 8.74 9.47 9.43 13 18 3.26 4.31 3.03 3.16 3.11
Amortization Expense		 0.00 - 0.00 0.00 8.50 -0.44 29 29 7.28 3.87 2.80
Non-Cash Adjustments To Reconcile Net Income		 1.69 1.47 18 6.51 8.84 15 12 15 288 16 19
Changes in Operating Assets and Liabilities, net		 -3.13 -4.09 1.44 7.13 -5.12 1.91 -7.06 -21 -22 6.83 -6.28
Net Cash From Investing Activities		 -32 -18 -17 -3.88 -186 -1.99 -305 -9.49 -81 -4.50 -3.25
Net Cash From Continuing Investing Activities		 -32 -18 -17 -3.88 -186 -1.99 -305 -9.49 -81 -4.50 -3.25
Purchase of Property, Plant & Equipment		 -7.73 -12 -2.80 -1.26 -1.50 -1.99 -4.43 -4.54 -2.57 -4.25 -3.25
Acquisitions		 -24 -6.80 -16 -4.84 -184 0.00 -301 -4.95 -79 -0.25 0.00
Net Cash From Financing Activities		 19 1.15 -9.02 -22 231 146 53 -33 33 -45 -42
Net Cash From Continuing Financing Activities		 19 1.15 -9.02 -22 231 146 53 -33 33 -45 -42
Repayment of Debt		 -6.00 -57 -20 -26 -28 -0.66 -21 -36 -34 -116 -135
Payment of Dividends		 -2.30 -2.36 -2.41 -2.46 -2.72 -3.17 -3.34 -3.41 -3.45 -3.47 -3.52
Issuance of Debt		 25 67 11 2.00 173 0.00 70 0.00 71 73 108
Other Financing Activities, net		 1.92 -6.04 2.01 4.42 4.93 4.12 7.15 6.08 -0.37 1.76 -11
Effect of Exchange Rate Changes		 -0.02 0.07 0.14 - -1.49 1.18 - -1.60 - - 1.88
Cash Interest Paid		 0.85 1.38 1.96 1.64 1.63 2.37 2.76 3.49 4.65 11 10
Cash Income Taxes Paid		 3.95 5.61 4.55 5.87 2.63 1.37 3.05 1.36 4.59 5.73 1.87

Quarterly Cash Flow Statements for Mesa Laboratories

This table details how cash moves in and out of Mesa Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2025 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -11 -6.28 6.81 -0.53 3.24 -7.39 -0.01 -6.04 -4.14 6.62 -24
Net Cash From Operating Activities		 11 7.72 13 9.94 9.78 12 13 1.89 5.27 18 13
Net Cash From Continuing Operating Activities		 11 7.72 13 9.94 9.78 12 13 1.89 5.27 18 -6.06
Net Income / (Loss) Continuing Operations		 1.31 0.45 0.61 -0.55 -1.23 2.12 -255 4.74 3.43 -1.68 -7.11
Consolidated Net Income / (Loss)		 1.31 0.45 0.61 -0.55 -1.23 2.12 -255 4.74 3.43 -1.68 -7.11
Depreciation Expense		 8.06 -13 1.12 0.91 0.91 1.07 1.33 1.40 1.52 1.11 -0.87
Amortization Expense		 - - 7.25 7.22 7.19 7.98 6.19 4.55 5.00 4.39 -10
Non-Cash Adjustments To Reconcile Net Income		 3.05 3.71 4.11 3.48 4.27 0.47 280 -0.86 1.33 11 2.67
Changes in Operating Assets and Liabilities, net		 -1.86 -5.02 -0.56 -1.13 -1.36 -0.10 -20 -7.95 -6.01 3.56 9.61
Net Cash From Investing Activities		 -1.64 -6.60 -1.03 -0.27 -0.63 -81 0.43 -1.01 -1.79 -0.81 -1.01
Net Cash From Continuing Investing Activities		 -1.64 -6.60 -1.03 -0.27 -0.63 -81 0.43 -1.01 -1.79 -0.81 -1.01
Purchase of Property, Plant & Equipment		 -1.64 -1.65 -1.03 -0.27 -0.63 -1.13 -0.54 -1.01 -1.79 -0.81 -0.76
Net Cash From Financing Activities		 -19 -8.88 -4.39 -9.52 -5.56 61 -13 -8.43 -8.61 -11 -16
Net Cash From Continuing Financing Activities		 -19 -8.88 -4.39 -9.52 -5.56 61 -13 -8.43 -8.61 -11 -16
Repayment of Debt		 -20 -8.00 -6.00 -8.66 -4.70 -9.29 -12 -8.50 -7.74 -9.73 -17
Payment of Dividends		 -0.85 -0.86 -0.86 -0.86 -0.86 -0.86 -0.86 -0.87 -0.87 -0.87 -0.87
Other Financing Activities, net		 2.21 -0.03 2.46 - - - -0.00 -9.56 - - 1.76

Annual Balance Sheets for Mesa Laboratories

This table presents Mesa Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets		 161 172 164 157 409 601 707 662 447 433 428
Total Current Assets		 37 36 32 34 123 304 124 119 109 103 106
Cash & Equivalents		 5.70 5.82 5.47 10 81 264 49 33 28 27 27
Accounts Receivable		 15 14 14 13 21 24 41 43 39 42 44
Inventories, net		 14 14 9.23 6.77 14 11 25 35 33 25 26
Prepaid Expenses		 0.94 1.19 0.78 1.60 1.91 4.92 9.14 8.87 9.41 8.03 8.87
Plant, Property, & Equipment, net		 17 26 24 22 22 22 29 28 32 32 31
Total Noncurrent Assets		 107 110 109 101 264 276 554 515 306 298 291
Goodwill		 66 72 66 66 142 161 291 286 180 182 187
Intangible Assets		 41 38 43 33 120 112 250 217 114 97 83
Noncurrent Deferred & Refundable Income Taxes		 - 0.00 0.13 1.32 0.36 0.62 1.32 1.08 1.29 1.37 1.50
Other Noncurrent Operating Assets		 - - - 0.00 2.48 2.53 12 10 11 18 19
Total Liabilities & Shareholders' Equity		 161 172 164 157 409 601 707 662 447 433 428
Total Liabilities		 76 74 65 45 189 195 314 268 301 274 242
Total Current Liabilities		 24 17 17 24 26 33 48 43 44 164 62
Short-Term Debt		 7.76 2.42 2.33 2.17 - - - - 0.00 101 5.63
Accounts Payable		 2.82 2.17 2.38 2.90 3.41 4.47 7.90 6.13 6.04 5.75 4.93
Accrued Expenses		 3.09 3.00 3.36 4.00 6.61 9.95 12 12 13 25 18
Current Deferred Revenue		 3.03 4.12 3.92 3.97 6.81 8.78 14 16 15 15 15
Current Employee Benefit Liabilities		 5.04 4.35 4.28 7.32 8.94 9.39 15 9.43 9.94 18 19
Total Noncurrent Liabilities		 52 57 47 22 163 163 266 225 257 110 180
Long-Term Debt		 42 54 45 21 140 146 218 183 222 77 146
Noncurrent Deferred & Payable Income Tax Liabilities		 5.42 3.55 2.62 1.08 21 16 39 34 20 20 20
Other Noncurrent Operating Liabilities		 4.43 0.12 0.19 0.11 1.36 0.72 7.92 7.69 16 12 14
Commitments & Contingencies		 0.00 0.00 - - - - - - - 0.00 0.00
Total Equity & Noncontrolling Interests		 85 98 99 111 220 406 394 393 145 160 186
Total Preferred & Common Equity		 85 98 99 111 220 406 394 393 145 160 186
Total Common Equity		 85 98 99 111 220 406 394 393 145 160 186
Common Stock		 21 26 31 40 158 318 313 332 344 359 375
Retained Earnings		 65 74 68 73 72 72 77 74 -183 -189 -186
Accumulated Other Comprehensive Income / (Loss)		 -1.15 -1.76 0.56 -1.82 -10 16 3.67 -13 -15 -9.78 -3.36

Quarterly Balance Sheets for Mesa Laboratories

This table presents Mesa Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2022 9/30/2022 12/31/2022 6/30/2023 9/30/2023 12/31/2023 6/30/2025 9/30/2025 12/31/2025
Total Assets		 686 656 663 643 637 742 436 430 435
Total Current Assets		 128 116 114 115 118 118 98 97 106
Cash & Equivalents		 44 32 26 32 36 28 21 20 29
Accounts Receivable		 42 42 42 36 36 36 39 40 40
Inventories, net		 27 28 34 36 33 36 28 28 27
Prepaid Expenses		 16 14 12 11 13 18 9.81 9.18 9.87
Plant, Property, & Equipment, net		 28 28 28 28 29 32 32 32 32
Total Noncurrent Assets		 530 512 521 500 491 592 306 301 298
Goodwill		 284 278 286 284 283 346 188 188 189
Intangible Assets		 235 222 223 205 198 233 97 93 90
Noncurrent Deferred & Refundable Income Taxes		 0.69 0.65 0.71 1.08 1.05 1.09 1.47 1.47 1.47
Other Noncurrent Operating Assets		 10 11 11 9.62 8.95 12 19 18 17
Total Liabilities & Shareholders' Equity		 686 656 663 643 637 742 436 430 435
Total Liabilities		 305 282 276 255 249 339 263 252 248
Total Current Liabilities		 44 42 42 39 40 44 149 48 54
Short-Term Debt		 - - - - - - 102 4.69 5.16
Accounts Payable		 7.56 7.74 6.29 5.59 4.81 4.55 6.27 5.09 5.25
Accrued Expenses		 12 12 13 11 12 16 16 14 16
Current Deferred Revenue		 15 14 15 15 14 14 15 14 15
Current Employee Benefit Liabilities		 9.40 7.48 8.13 7.27 8.35 9.38 10 10 14
Total Noncurrent Liabilities		 261 240 234 216 210 295 114 204 194
Long-Term Debt		 217 197 189 176 171 233 80 170 161
Noncurrent Deferred & Payable Income Tax Liabilities		 37 37 37 34 33 44 22 22 22
Other Noncurrent Operating Liabilities		 7.34 6.83 8.17 6.76 5.44 17 13 12 11
Total Equity & Noncontrolling Interests		 380 374 387 388 388 403 172 178 187
Total Preferred & Common Equity		 380 374 387 388 388 403 172 178 187
Total Common Equity		 380 374 387 388 388 403 172 178 187
Common Stock		 318 325 327 334 338 341 361 365 369
Retained Earnings		 74 75 74 73 71 72 -185 -183 -181
Accumulated Other Comprehensive Income / (Loss)		 -12 -26 -14 -19 -21 -9.84 -3.80 -3.23 -1.14

Annual Metrics And Ratios for Mesa Laboratories

This table displays calculated financial ratios and metrics derived from Mesa Laboratories' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 3,626,528.00 3,700,704.00 3,783,158.00 3,868,491.00 4,370,468.00 5,132,003.00 - - - 5,433,607.00 5,524,813.00
DEI Adjusted Shares Outstanding		 3,626,528.00 3,700,704.00 3,783,158.00 3,868,491.00 4,370,468.00 5,132,003.00 - - - 5,433,607.00 5,524,813.00
DEI Earnings Per Adjusted Shares Outstanding		 31.43 31.79 -0.78 1.93 0.41 0.64 - - - -0.36 1.21
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 137.37% 10.64% -48.66% 7.23% 14.11% 13.81% 37.63% 18.85% -1.32% 11.47% 3.38%
EBITDA Growth		 8.22% 1.34% -49.55% 70.15% 56.08% -10.72% 45.15% -6.19% -732.14% 108.46% 30.30%
EBIT Growth		 1.36% -8.09% -84.97% 381.29% -9.45% 10.26% -27.77% -41.27% -6,261.86% 105.53% 52.05%
NOPAT Growth		 18.32% 8.88% -268.34% 139.52% -57.03% 381.64% -85.99% -5.59% -8,295.03% 97.16% 291.17%
Net Income Growth		 16.55% 0.13% -126.49% 352.67% -76.24% 84.14% -42.85% -50.29% -27,438.28% 99.22% 440.02%
EPS Growth		 12.93% -2.02% -127.15% 335.44% -77.96% 56.10% -45.31% -51.43% -27,864.71% 99.24% 436.11%
Operating Cash Flow Growth		 56.28% 2.37% 48.63% 18.80% -11.67% 37.37% 5.80% -28.66% 57.71% 6.06% -8.50%
Free Cash Flow Firm Growth		 -33.48% 65.44% -94.10% 290.90% -743.87% 105.58% -3,325.63% 107.82% -31.87% 58.55% -56.54%
Invested Capital Growth		 30.40% 14.81% -6.19% -10.81% 125.09% 3.27% 95.40% -3.37% -37.69% -8.39% 0.11%
Revenue Q/Q Growth		 115.95% 4.75% -48.64% -0.42% 7.06% 2.89% 12.80% -1.48% 1.56% 0.39% 0.00%
EBITDA Q/Q Growth		 11.04% -2.49% 44.76% -20.81% 18.81% 5.33% 0.19% -6.12% -720.16% 109.55% 0.00%
EBIT Q/Q Growth		 12.98% -4.98% 298.61% -32.46% -15.41% 115.06% -44.50% -0.66% -5,973.61% 105.85% 0.00%
NOPAT Q/Q Growth		 16.72% -0.98% -3,579.41% -22.56% -49.84% 174.17% -69.63% 23.28% -99,197.45% 96.96% 0.00%
Net Income Q/Q Growth		 18.60% -3.02% 17.10% -27.59% -61.90% 253.49% -75.30% 163.48% -26,919.20% 99.19% 0.00%
EPS Q/Q Growth		 17.39% -3.96% 21.00% -30.34% -64.96% 218.52% -75.86% 158.62% -26,322.22% 99.21% 0.00%
Operating Cash Flow Q/Q Growth		 15.83% 26.11% -3.35% 2.07% -5.03% 14.48% -9.71% 12.99% 0.83% 12.11% 0.00%
Free Cash Flow Firm Q/Q Growth		 11.48% -24.55% -394.63% 0.77% 6.16% 209.38% -3.82% -16.46% 125.13% -78.27% 0.00%
Invested Capital Q/Q Growth		 -0.06% 0.71% -3.18% -5.50% -6.93% -5.05% -1.91% -1.15% -44.24% -4.13% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 60.73% 56.84% 56.79% 59.06% 55.54% 64.97% 59.18% 61.02% 61.64% 62.61% 63.53%
EBITDA Margin		 13.42% 12.30% 12.08% 19.17% 26.22% 20.57% 21.69% 17.12% -109.70% 9.12% 11.49%
Operating Margin		 9.64% 8.71% 2.27% 9.48% 6.73% 9.23% 2.55% 1.52% -125.85% 6.78% 7.43%
EBIT Margin		 9.19% 7.63% 2.23% 10.03% 7.96% 7.71% 4.05% 2.00% -124.87% 6.20% 9.11%
Profit (Net Income) Margin		 6.60% 5.97% -3.08% 7.26% 1.51% 2.44% 1.02% 0.42% -117.60% -0.82% 2.69%
Tax Burden Percent		 71.80% 78.22% -984.05% 86.79% 46.04% 142.16% 52.35% -239.07% 92.24% -33.12% 55.87%
Interest Burden Percent		 100.00% 100.00% 14.01% 83.37% 41.23% 22.30% 47.92% -8.88% 102.11% 39.92% 52.91%
Effective Tax Rate		 28.20% 21.78% 1,084.05% 13.21% 53.96% -42.16% 47.65% 0.00% 0.00% 133.12% 44.13%
Return on Invested Capital (ROIC)		 10.29% 9.21% -14.97% 6.46% 1.81% 6.20% 0.58% 0.42% -43.15% -1.67% 3.33%
ROIC Less NNEP Spread (ROIC-NNEP)		 8.70% 5.87% 26.26% 2.61% -3.42% 54.41% -1.74% -0.45% -80.26% 0.33% 0.69%
Return on Net Nonoperating Assets (RNNOA)		 3.84% 3.04% 11.96% 0.65% -0.74% -5.15% -0.11% -0.18% -51.21% 0.37% 0.55%
Return on Equity (ROE)		 14.12% 12.26% -3.00% 7.10% 1.07% 1.05% 0.47% 0.24% -94.36% -1.29% 3.88%
Cash Return on Invested Capital (CROIC)		 -16.11% -4.58% -8.58% 17.89% -75.15% 2.98% -64.01% 3.85% 3.29% 7.09% 3.22%
Operating Return on Assets (OROA)		 11.19% 8.60% 1.28% 6.45% 3.31% 2.04% 1.14% 0.64% -48.70% 3.39% 5.27%
Return on Assets (ROA)		 8.03% 6.73% -1.76% 4.66% 0.63% 0.65% 0.29% 0.14% -45.87% -0.45% 1.56%
Return on Common Equity (ROCE)		 14.12% 12.26% -3.00% 7.10% 1.07% 1.05% 0.47% 0.24% -94.36% -1.29% 3.88%
Return on Equity Simple (ROE_SIMPLE)		 13.19% 11.43% -2.98% 6.72% 0.81% 0.81% 0.48% 0.24% -174.87% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 12 13 -21 8.49 3.65 18 2.46 2.32 -190 -5.41 10
NOPAT Margin		 6.92% 6.81% -22.34% 8.23% 3.10% 13.12% 1.34% 1.06% -88.10% -2.24% 4.15%
Net Nonoperating Expense Percent (NNEP)		 1.58% 3.34% -41.23% 3.85% 5.23% -48.22% 2.32% 0.87% 37.11% -2.00% 2.64%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -1.60% 3.06%
Cost of Revenue to Revenue		 39.27% 43.16% 43.21% 40.94% 44.46% 35.03% 40.82% 38.98% 38.36% 37.39% 36.47%
SG&A Expenses to Revenue		 18.38% 17.49% 36.47% 38.35% 43.41% 47.98% 48.08% 50.16% 51.57% 47.73% 47.95%
R&D to Revenue		 2.35% 2.22% 3.68% 3.40% 5.40% 7.76% 8.55% 9.35% 8.93% 8.10% 8.15%
Operating Expenses to Revenue		 -9.64% -8.71% 54.52% 49.58% 48.81% 55.74% 56.63% 59.51% 187.49% 55.83% 56.10%
Earnings before Interest and Taxes (EBIT)		 16 14 2.15 10 9.37 10 7.46 4.38 -270 15 23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 23 23 12 20 31 28 40 38 -237 22 29
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.00 4.52 5.53 7.87 4.42 3.04 3.36 2.36 4.07 4.00 2.62
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 74.75 0.00 9.23 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.00 2.36 5.72 8.49 8.27 9.21 7.18 4.23 2.73 2.65 1.96
Price to Earnings (P/E)		 2.97 3.76 0.00 117.01 547.24 376.77 707.10 997.39 0.00 0.00 72.67
Dividend Yield		 0.69% 0.54% 0.44% 0.28% 0.29% 0.27% 0.25% 0.37% 0.58% 0.54% 0.72%
Earnings Yield		 33.67% 26.59% 0.00% 0.85% 0.18% 0.27% 0.14% 0.10% 0.00% 0.00% 1.38%
Enterprise Value to Invested Capital (EV/IC)		 2.97 3.33 4.26 7.17 3.70 3.87 2.65 1.98 2.32 2.54 1.97
Enterprise Value to Revenue (EV/Rev)		 2.26 2.63 6.15 8.61 8.77 8.33 8.09 4.92 3.63 3.28 2.46
Enterprise Value to EBITDA (EV/EBITDA)		 16.85 21.39 50.88 44.93 33.44 40.48 37.31 28.73 0.00 35.94 21.39
Enterprise Value to EBIT (EV/EBIT)		 24.62 34.47 275.11 85.88 110.17 108.00 200.03 246.05 0.00 52.87 26.97
Enterprise Value to NOPAT (EV/NOPAT)		 32.67 38.61 0.00 104.64 282.90 63.49 606.13 463.83 0.00 0.00 59.21
Enterprise Value to Operating Cash Flow (EV/OCF)		 22.65 28.47 22.99 29.07 38.24 30.09 38.04 38.52 17.78 16.87 14.30
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 37.79 0.00 132.11 0.00 50.60 54.06 34.31 61.23
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.59 0.57 0.47 0.20 0.64 0.36 0.55 0.47 1.52 1.11 0.81
Long-Term Debt to Equity		 0.50 0.55 0.45 0.19 0.64 0.36 0.55 0.47 1.52 0.48 0.78
Financial Leverage		 0.44 0.52 0.46 0.25 0.22 -0.09 0.06 0.41 0.64 1.13 0.80
Leverage Ratio		 1.76 1.82 1.70 1.52 1.71 1.61 1.64 1.74 2.06 2.88 2.49
Compound Leverage Factor		 1.76 1.82 0.24 1.27 0.70 0.36 0.78 -0.15 2.10 1.15 1.32
Debt to Total Capital		 37.13% 36.44% 32.10% 16.99% 38.93% 26.40% 35.67% 31.78% 60.39% 52.68% 44.85%
Short-Term Debt to Total Capital		 5.76% 1.57% 1.60% 1.62% 0.00% 0.00% 0.00% 0.00% 0.00% 29.92% 1.67%
Long-Term Debt to Total Capital		 31.37% 34.87% 30.50% 15.37% 38.93% 26.40% 35.67% 31.78% 60.39% 22.77% 43.19%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 62.87% 63.56% 67.90% 83.01% 61.07% 73.60% 64.33% 68.22% 39.61% 47.32% 55.15%
Debt to EBITDA		 2.20 2.44 4.04 1.15 4.55 5.29 5.46 4.89 -0.93 8.10 5.29
Net Debt to EBITDA		 1.95 2.18 3.57 0.64 1.91 -4.29 4.23 4.01 -0.82 6.86 4.35
Long-Term Debt to EBITDA		 1.86 2.33 3.84 1.04 4.55 5.29 5.46 4.89 -0.93 3.50 5.10
Debt to NOPAT		 4.27 4.40 -2.19 2.68 38.46 8.29 88.71 78.86 -1.16 -32.89 14.65
Net Debt to NOPAT		 3.78 3.94 -1.93 1.48 16.15 -6.73 68.66 64.70 -1.02 -27.84 12.04
Long-Term Debt to NOPAT		 3.60 4.21 -2.08 2.43 38.46 8.29 88.71 78.86 -1.16 -14.22 14.10
Altman Z-Score		 4.71 5.69 6.41 13.17 3.98 4.78 3.11 2.72 -0.73 1.29 1.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.55 2.16 1.85 1.42 4.72 9.32 2.59 2.74 2.47 0.63 1.72
Quick Ratio		 0.88 1.22 1.14 0.96 3.94 8.83 1.88 1.74 1.52 0.42 1.15
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -6.34 -12 24 -151 8.44 -272 21 15 23 10
Operating Cash Flow to CapEx		 218.70% 149.11% 1,543.76% 0.00% 1,819.82% 1,861.09% 885.00% 615.82% 1,719.24% 1,101.62% 1,317.88%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -6.65 13.44 -27.50 1.05 -70.10 4.47 2.55 2.56 0.94
Operating Cash Flow to Interest Expense		 0.00 0.00 13.88 17.47 4.90 4.62 10.10 5.87 7.75 5.22 4.01
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 12.98 18.02 4.63 4.37 8.96 4.91 7.30 4.74 3.70
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.22 1.13 0.57 0.64 0.42 0.27 0.28 0.32 0.39 0.55 0.58
Accounts Receivable Turnover		 12.33 12.64 6.72 7.69 7.00 5.96 5.67 5.23 5.30 5.95 5.79
Inventory Turnover		 5.03 5.80 3.60 5.28 4.98 3.69 4.21 2.88 2.46 3.11 3.51
Fixed Asset Turnover		 12.91 8.79 3.88 4.50 5.31 6.08 7.28 7.72 7.22 7.52 7.92
Accounts Payable Turnover		 24.97 32.40 18.28 16.00 16.60 11.91 12.17 12.17 13.62 15.29 17.02
Days Sales Outstanding (DSO)		 29.60 28.87 54.31 47.46 52.18 61.21 64.36 69.79 68.89 61.36 63.05
Days Inventory Outstanding (DIO)		 72.56 62.95 101.44 69.16 73.25 98.82 86.79 126.63 148.13 117.55 103.92
Days Payable Outstanding (DPO)		 14.62 11.27 19.97 22.82 21.99 30.65 30.00 29.99 26.79 23.87 21.44
Cash Conversion Cycle (CCC)		 87.54 80.56 135.78 93.80 103.44 129.37 121.15 166.43 190.23 155.04 145.53
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 129 148 139 124 279 288 563 544 339 310 311
Invested Capital Turnover		 1.49 1.35 0.67 0.78 0.58 0.47 0.43 0.40 0.49 0.74 0.80
Increase / (Decrease) in Invested Capital		 30 19 -9.17 -15 155 9.13 275 -19 -205 -28 0.34
Enterprise Value (EV)		 383 493 591 888 1,032 1,115 1,492 1,078 785 790 612
Market Capitalization		 339 442 550 876 973 1,234 1,323 928 591 639 488
Book Value per Share		 $23.35 $26.43 $26.26 $28.77 $50.34 $79.16 $75.07 $73.60 $26.95 $29.42 $33.71
Tangible Book Value per Share		 ($6.14) ($3.28) ($2.39) $3.03 ($9.47) $26.04 ($28.11) ($20.53) ($27.52) ($21.86) ($15.20)
Total Capital		 135 154 146 134 360 552 612 577 367 338 338
Total Debt		 50 56 47 23 140 146 218 183 222 178 151
Total Long-Term Debt		 42 54 45 21 140 146 218 183 222 77 146
Net Debt		 44 50 42 13 59 -118 169 150 193 151 125
Capital Expenditures (CapEx)		 7.73 12 1.67 -0.96 1.48 1.99 4.43 4.54 2.57 4.25 3.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 15 16 12 1.95 15 7.30 27 43 37 12 23
Debt-free Net Working Capital (DFNWC)		 21 22 17 12 97 271 76 76 65 40 50
Net Working Capital (NWC)		 13 19 15 9.96 97 271 76 76 65 -61 44
Net Nonoperating Expense (NNE)		 0.55 1.58 -19 1.01 1.87 14 0.59 1.39 64 -3.44 3.63
Net Nonoperating Obligations (NNO)		 44 50 40 13 59 -118 169 150 193 151 125
Total Depreciation and Amortization (D&A)		 7.17 8.74 9.47 9.43 21 17 33 33 33 7.03 5.92
Debt-free, Cash-free Net Working Capital to Revenue		 9.02% 8.44% 12.02% 1.89% 13.09% 5.45% 14.60% 19.49% 17.03% 5.17% 9.26%
Debt-free Net Working Capital to Revenue		 12.39% 11.55% 17.71% 11.76% 82.24% 202.46% 41.37% 34.52% 30.09% 16.50% 20.07%
Net Working Capital to Revenue		 7.80% 10.26% 15.28% 9.66% 82.24% 202.46% 41.37% 34.52% 30.09% -25.43% 17.81%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $3.10 $3.04 ($0.79) $1.95 $0.32 $0.66 $0.36 $0.17 ($47.20) ($0.36) $1.22
Adjusted Weighted Average Basic Shares Outstanding		 3.61M 3.68M 3.77M 3.84M 4.20M 4.98M 5.21M 5.32M 5.39M 5.42M 5.51M
Adjusted Diluted Earnings per Share		 $2.97 $2.91 ($0.79) $1.86 $0.31 $0.64 $0.35 $0.17 ($47.20) ($0.36) $1.21
Adjusted Weighted Average Diluted Shares Outstanding		 3.76M 3.84M 3.77M 4.03M 4.37M 5.12M 5.34M 5.36M 5.39M 5.42M 5.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.64M 3.74M 3.81M 3.90M 4.39M 5.14M 5.27M 5.37M 5.41M 5.46M 5.52M
Normalized Net Operating Profit after Tax (NOPAT)		 12 13 11 15 5.55 8.65 2.46 2.32 1.72 11 10
Normalized NOPAT Margin		 6.92% 6.81% 11.65% 15.03% 4.71% 6.46% 1.34% 1.06% 0.80% 4.75% 4.15%
Pre Tax Income Margin		 9.19% 7.63% 0.31% 8.36% 3.28% 1.72% 1.94% -0.18% -127.50% 2.47% 4.82%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 1.16 5.91 1.70 1.29 1.92 0.92 -47.38 1.66 2.12
NOPAT to Interest Expense		 0.00 0.00 -11.59 4.85 0.66 2.19 0.63 0.49 -33.43 -0.60 0.97
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.26 6.46 1.43 1.04 0.78 -0.03 -47.84 1.19 1.82
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -12.49 5.40 0.39 1.94 -0.51 -0.47 -33.88 -1.08 0.66
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 20.62% 21.06% -81.47% 32.90% 153.09% 96.67% 178.46% 366.24% -1.36% -175.68% 52.49%
Augmented Payout Ratio		 20.62% 21.06% -81.47% 32.90% 153.09% 96.67% 178.46% 366.24% -1.36% -175.68% 52.49%

Quarterly Metrics And Ratios for Mesa Laboratories

This table displays calculated financial ratios and metrics derived from Mesa Laboratories' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 5,433,607.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 5,433,607.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -2.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 63.92% -0.75% -5.58% 0.38% -9.50% -1.50% 5.96% 14.86% 8.78% 17.52% 1.60%
EBITDA Growth		 31.32% -279.82% -20.53% 120.69% -39.33% 229.61% -2,908.62% 18.78% 73.94% -52.36% 94.93%
EBIT Growth		 -14.18% 332.65% -2.56% 102.52% -109.13% 23.52% -24,890.93% 3,098.20% 1,726.19% -83.56% 98.76%
NOPAT Growth		 -55.18% 145.54% 570.00% 85.55% -102.72% -109.10% -52,572.73% 1,141.57% 7,611.01% 5,652.69% 99.73%
Net Income Growth		 -64.89% 121.89% 134.25% 61.82% -194.18% 369.18% -41,766.61% 717.12% 378.70% -179.21% 95.12%
EPS Growth		 -65.71% 120.51% 135.29% 62.96% -195.83% 387.50% -39,483.33% 720.00% 373.91% -179.49% 95.22%
Operating Cash Flow Growth		 138.09% -51.45% 34.58% 453.58% -7.40% 49.46% 2.91% 4.97% -46.08% 59.85% -1.69%
Free Cash Flow Firm Growth		 -3,457.26% 108.97% 107.04% 108.30% 106.38% -336.02% -22.10% 815.96% 1,067.24% 606.31% 85.25%
Invested Capital Growth		 85.72% -4.12% -3.37% -4.05% -2.93% 10.46% -37.69% -36.99% -34.57% -47.35% -8.39%
Revenue Q/Q Growth		 16.44% -7.60% 2.40% -8.90% 4.98% 0.58% 10.16% -1.25% -0.58% 8.66% -4.76%
EBITDA Q/Q Growth		 238.68% -178.36% 195.49% -12.92% -6.90% 67.42% -2,690.64% 103.68% 36.34% -54.15% -330.57%
EBIT Q/Q Growth		 204.55% -33.06% -64.17% -89.94% -478.38% 1,005.24% -7,292.11% 101.30% 92.39% -90.85% -642.24%
NOPAT Q/Q Growth		 147.94% -48.06% -54.81% -228.43% 90.96% -73.46% -260,560.23% 102.55% -34.84% 28.23% -112.58%
Net Income Q/Q Growth		 190.82% -65.47% 35.48% -189.85% -124.04% 272.03% -12,131.33% 101.33% 1.18% -148.89% -641.05%
EPS Q/Q Growth		 188.89% -66.67% 50.00% -183.33% -130.00% 269.57% -12,217.95% 101.31% 1.61% -149.21% -629.03%
Operating Cash Flow Q/Q Growth		 475.56% -26.89% 62.21% -20.61% -1.64% 17.99% 11.69% -19.02% -49.48% 249.82% -32.47%
Free Cash Flow Firm Q/Q Growth		 6.58% 109.88% -20.79% 13.57% -28.26% -465.70% 126.14% 1,235.32% -8.57% 58.63% -90.31%
Invested Capital Q/Q Growth		 -2.64% 2.13% -1.15% -2.39% -1.50% 16.22% -44.24% -1.29% 2.27% -6.47% -4.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 61.93% 60.36% 59.72% 61.57% 60.40% 62.47% 62.06% 64.03% 61.31% 63.26% 60.77%
EBITDA Margin		 21.54% -18.26% 17.03% 16.28% 14.44% 24.03% -451.45% 16.84% 23.09% 9.74% -24.42%
Operating Margin		 6.80% 6.27% 0.93% -1.31% -0.11% -0.13% -460.55% 9.59% 6.07% 9.20% -1.21%
EBIT Margin		 7.83% 5.67% 1.98% 0.22% -0.79% 7.11% -464.22% 6.10% 11.81% 0.99% -5.66%
Profit (Net Income) Margin		 2.22% 0.83% 1.10% -1.08% -2.31% 3.96% -432.20% 5.82% 5.93% -2.67% -20.75%
Tax Burden Percent		 38.59% 23.54% -220.58% 58.59% 92.83% 108.74% 92.46% 86.76% 89.93% 75.60% 195.53%
Interest Burden Percent		 73.60% 62.25% -25.11% -844.14% 315.48% 51.18% 100.69% 110.00% 55.81% -354.72% 187.43%
Effective Tax Rate		 61.41% 76.46% 0.00% 0.00% 0.00% -8.74% 0.00% 13.24% 10.07% 0.00% 0.00%
Return on Invested Capital (ROIC)		 1.41% 0.58% 0.26% -0.37% -0.03% -0.05% -157.91% 4.30% 2.88% 3.30% -0.63%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.55% 0.38% 0.41% -0.42% -0.83% 1.14% -195.54% 3.41% 3.05% 0.20% -7.55%
Return on Net Nonoperating Assets (RNNOA)		 0.04% 0.16% 0.17% -0.17% -0.32% 0.53% -124.77% 2.07% 1.76% 0.13% -8.52%
Return on Equity (ROE)		 1.45% 0.75% 0.43% -0.55% -0.36% 0.48% -282.68% 6.38% 4.64% 3.43% -9.15%
Cash Return on Invested Capital (CROIC)		 -60.55% 4.54% 3.85% 4.73% 3.40% -9.97% 3.29% 2.37% -0.65% 23.33% 7.09%
Operating Return on Assets (OROA)		 2.76% 1.82% 0.63% 0.07% -0.26% 2.15% -181.05% 2.52% 4.94% 0.40% -3.10%
Return on Assets (ROA)		 0.78% 0.27% 0.35% -0.36% -0.76% 1.20% -168.56% 2.41% 2.48% -1.08% -11.36%
Return on Common Equity (ROCE)		 1.45% 0.75% 0.43% -0.55% -0.36% 0.48% -282.68% 6.38% 4.64% 3.43% -9.15%
Return on Equity Simple (ROE_SIMPLE)		 -1.06% -0.38% 0.00% 0.47% -0.18% 0.24% 0.00% -166.07% -152.15% -160.71% 0.00%
Net Operating Profit after Tax (NOPAT)		 1.54 0.80 0.36 -0.46 -0.04 -0.07 -190 4.84 3.15 4.05 -0.51
NOPAT Margin		 2.62% 1.48% 0.65% -0.92% -0.08% -0.14% -322.39% 8.32% 5.45% 6.44% -0.85%
Net Nonoperating Expense Percent (NNEP)		 0.86% 0.21% -0.16% 0.05% 0.79% -1.19% 37.62% 0.89% -0.17% 3.10% 6.92%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -0.01% - - - 1.15% -0.15%
Cost of Revenue to Revenue		 38.07% 39.64% 40.28% 38.43% 39.61% 37.53% 37.94% 35.97% 38.69% 36.74% 39.23%
SG&A Expenses to Revenue		 46.64% 45.25% 49.79% 53.38% 51.12% 54.56% 47.71% 46.30% 47.23% 46.02% 53.43%
R&D to Revenue		 8.49% 8.84% 9.00% 9.50% 9.39% 8.03% 8.83% 8.14% 8.01% 8.04% 8.55%
Operating Expenses to Revenue		 55.13% 54.09% 58.79% 62.88% 60.51% 62.59% 522.61% 54.44% 55.24% 54.07% 61.99%
Earnings before Interest and Taxes (EBIT)		 4.60 3.08 1.10 0.11 -0.42 3.80 -273 3.55 6.83 0.63 -3.39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 13 -9.92 9.47 8.25 7.68 13 -266 9.79 13 6.12 -15
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.98 2.27 2.36 1.77 1.45 1.39 4.07 3.11 4.35 4.61 4.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.33 3.96 4.23 3.13 2.63 2.64 2.73 2.10 3.08 3.01 2.65
Price to Earnings (P/E)		 0.00 0.00 997.39 377.12 0.00 592.62 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.46% 0.39% 0.37% 0.50% 0.61% 0.61% 0.58% 0.74% 0.49% 0.49% 0.54%
Earnings Yield		 0.00% 0.00% 0.10% 0.27% 0.00% 0.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.68 1.90 1.98 1.56 1.33 1.26 2.32 1.95 2.58 2.75 2.54
Enterprise Value to Revenue (EV/Rev)		 4.07 4.69 4.92 3.78 3.26 3.60 3.63 2.92 3.87 3.71 3.28
Enterprise Value to EBITDA (EV/EBITDA)		 85.44 26.10 28.73 138.58 0.00 20.05 0.00 0.00 0.00 0.00 35.94
Enterprise Value to EBIT (EV/EBIT)		 100,734.97 236.49 246.05 93.26 180.14 166.79 0.00 0.00 0.00 0.00 52.87
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 553.24 463.83 256.88 311.86 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 27.52 42.11 38.52 20.35 17.46 17.51 17.78 14.64 22.01 18.73 16.87
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 40.90 50.60 32.32 38.67 0.00 54.06 63.66 0.00 8.14 34.31
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.53 0.49 0.47 0.45 0.44 0.58 1.52 1.41 1.27 1.26 1.11
Long-Term Debt to Equity		 0.53 0.49 0.47 0.45 0.44 0.58 1.52 1.38 0.65 0.61 0.48
Financial Leverage		 0.07 0.43 0.41 0.41 0.39 0.47 0.64 0.61 0.57 0.66 1.13
Leverage Ratio		 1.64 1.77 1.74 1.73 1.70 1.78 2.06 2.01 1.99 2.11 2.88
Compound Leverage Factor		 1.20 1.10 -0.44 -14.60 5.35 0.91 2.07 2.21 1.11 -7.49 5.40
Debt to Total Capital		 34.47% 32.81% 31.78% 31.16% 30.57% 36.63% 60.39% 58.47% 55.94% 55.77% 52.68%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.03% 27.50% 28.76% 29.92%
Long-Term Debt to Total Capital		 34.47% 32.81% 31.78% 31.16% 30.57% 36.63% 60.39% 57.44% 28.44% 27.01% 22.77%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 65.53% 67.19% 68.22% 68.84% 69.43% 63.37% 39.61% 41.53% 44.06% 44.23% 47.32%
Debt to EBITDA		 18.55 4.73 4.89 29.33 -27.63 6.09 -0.93 -0.90 -0.89 -0.83 8.10
Net Debt to EBITDA		 15.50 4.08 4.01 23.92 -21.87 5.35 -0.82 -0.78 -0.79 -0.70 6.86
Long-Term Debt to EBITDA		 18.55 4.73 4.89 29.33 -27.63 6.09 -0.93 -0.89 -0.45 -0.40 3.50
Debt to NOPAT		 -87.29 100.28 78.86 54.38 76.34 -1,214.62 -1.16 -1.14 -1.12 -1.09 -32.89
Net Debt to NOPAT		 -72.93 86.44 64.70 44.35 60.41 -1,067.47 -1.02 -0.99 -0.98 -0.92 -27.84
Long-Term Debt to NOPAT		 -87.29 100.28 78.86 54.38 76.34 -1,214.62 -1.16 -1.12 -0.57 -0.53 -14.22
Altman Z-Score		 2.24 2.55 2.70 2.26 1.99 1.55 -0.76 1.07 1.32 1.37 1.15
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.80 2.74 2.74 2.93 2.96 2.68 2.47 1.94 0.70 0.71 0.63
Quick Ratio		 1.79 1.65 1.74 1.74 1.81 1.45 1.52 1.17 0.42 0.45 0.42
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -247 24 19 22 16 -58 15 201 184 292 28
Operating Cash Flow to CapEx		 644.11% 466.63% 1,220.18% 3,681.11% 1,541.96% 1,022.61% 2,408.04% 1,170.93% 294.80% 2,268.02% 1,673.05%
Free Cash Flow to Firm to Interest Expense		 -203.54 21.01 14.01 20.96 17.41 -31.05 7.98 0.00 60.95 102.66 9.42
Operating Cash Flow to Interest Expense		 8.70 6.64 9.07 9.48 10.80 6.22 6.82 0.00 1.75 6.49 4.27
Operating Cash Flow Less CapEx to Interest Expense		 7.35 5.22 8.33 9.23 10.10 5.61 6.54 0.00 1.15 6.20 4.02
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.35 0.32 0.32 0.33 0.33 0.30 0.39 0.41 0.42 0.40 0.55
Accounts Receivable Turnover		 6.91 5.58 5.23 5.66 5.47 5.43 5.30 6.29 5.96 6.37 5.95
Inventory Turnover		 4.55 3.02 2.88 2.75 2.77 2.38 2.46 2.51 2.74 2.77 3.11
Fixed Asset Turnover		 8.80 7.61 7.72 7.84 7.52 7.09 7.22 7.54 7.53 7.50 7.52
Accounts Payable Turnover		 14.97 12.29 12.17 13.04 13.46 15.31 13.62 15.01 15.88 20.54 15.29
Days Sales Outstanding (DSO)		 52.79 65.40 69.79 64.45 66.74 67.23 68.89 58.05 61.19 57.32 61.36
Days Inventory Outstanding (DIO)		 80.26 120.86 126.63 132.90 131.68 153.32 148.13 145.59 133.32 131.83 117.55
Days Payable Outstanding (DPO)		 24.39 29.69 29.99 27.98 27.12 23.85 26.79 24.32 22.99 17.77 23.87
Cash Conversion Cycle (CCC)		 108.67 156.57 166.43 169.36 171.30 196.70 190.23 179.32 171.52 171.37 155.04
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 539 550 544 531 523 608 339 335 342 320 310
Invested Capital Turnover		 0.54 0.40 0.40 0.40 0.40 0.37 0.49 0.52 0.53 0.51 0.74
Increase / (Decrease) in Invested Capital		 249 -24 -19 -22 -16 58 -205 -196 -181 -288 -28
Enterprise Value (EV)		 907 1,043 1,078 829 697 767 785 653 883 881 790
Market Capitalization		 742 880 928 686 562 562 591 469 702 716 639
Book Value per Share		 $70.38 $72.55 $73.60 $72.20 $72.02 $74.74 $26.95 $27.87 $29.85 $28.58 $29.42
Tangible Book Value per Share		 ($23.70) ($22.87) ($20.53) ($18.89) ($17.31) ($32.64) ($27.52) ($25.60) ($24.24) ($22.12) ($21.86)
Total Capital		 571 576 577 563 558 636 367 363 366 351 338
Total Debt		 197 189 183 176 171 233 222 212 205 196 178
Total Long-Term Debt		 197 189 183 176 171 233 222 208 104 95 77
Net Debt		 164 163 150 143 135 205 193 184 181 165 151
Capital Expenditures (CapEx)		 1.64 1.65 1.03 0.27 0.63 1.13 0.54 0.89 1.79 0.81 0.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 42 46 43 43 42 46 37 27 31 25 12
Debt-free Net Working Capital (DFNWC)		 75 73 76 76 78 74 65 56 56 56 40
Net Working Capital (NWC)		 75 73 76 76 78 74 65 52 -45 -45 -61
Net Nonoperating Expense (NNE)		 0.24 0.35 -0.25 0.08 1.19 -2.19 65 1.45 -0.27 5.72 12
Net Nonoperating Obligations (NNO)		 164 163 150 143 135 205 193 184 181 165 151
Total Depreciation and Amortization (D&A)		 8.06 -13 8.37 8.13 8.10 9.05 7.52 6.24 6.52 5.50 -11
Debt-free, Cash-free Net Working Capital to Revenue		 19.02% 20.90% 19.49% 19.75% 19.76% 21.58% 17.03% 12.12% 13.66% 10.48% 5.17%
Debt-free Net Working Capital to Revenue		 33.56% 32.63% 34.52% 34.52% 36.43% 34.84% 30.09% 24.84% 24.31% 23.50% 16.50%
Net Working Capital to Revenue		 33.56% 32.63% 34.52% 34.52% 36.43% 34.84% 30.09% 23.17% -19.81% -18.94% -25.43%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.25 $0.08 $0.11 ($0.10) ($0.23) $0.39 ($47.26) $0.63 $0.63 ($0.31) ($2.28)
Adjusted Weighted Average Basic Shares Outstanding		 5.32M 5.34M 5.32M 5.37M 5.39M 5.39M 5.39M 5.40M 5.41M 5.43M 5.42M
Adjusted Diluted Earnings per Share		 $0.24 $0.08 $0.12 ($0.10) ($0.23) $0.39 ($47.26) $0.62 $0.63 ($0.31) ($2.26)
Adjusted Weighted Average Diluted Shares Outstanding		 5.36M 5.36M 5.36M 5.37M 5.39M 5.40M 5.39M 5.42M 5.47M 5.43M 5.42M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.34M 5.35M 5.37M 5.38M 5.39M 5.39M 5.41M 5.41M 5.43M 5.43M 5.46M
Normalized Net Operating Profit after Tax (NOPAT)		 2.80 2.38 0.36 -0.46 -0.04 -0.05 -190 4.84 3.15 4.05 -0.51
Normalized NOPAT Margin		 4.76% 4.39% 0.65% -0.92% -0.08% -0.09% -322.39% 8.32% 5.45% 6.44% -0.85%
Pre Tax Income Margin		 5.76% 3.53% -0.50% -1.85% -2.49% 3.64% -467.43% 6.71% 6.59% -3.53% -10.61%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 3.79 2.65 0.80 0.11 -0.46 2.05 -144.83 0.00 2.26 0.22 -1.14
NOPAT to Interest Expense		 1.27 0.69 0.26 -0.44 -0.05 -0.04 -100.58 0.00 1.05 1.42 -0.17
EBIT Less CapEx to Interest Expense		 2.44 1.23 0.06 -0.15 -1.16 1.44 -145.12 0.00 1.67 -0.07 -1.40
NOPAT Less CapEx to Interest Expense		 -0.08 -0.73 -0.48 -0.70 -0.75 -0.65 -100.87 0.00 0.45 1.14 -0.43
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -84.91% -231.67% 366.24% 188.13% -478.66% 362.76% -1.36% -1.38% -1.41% -1.39% -175.68%
Augmented Payout Ratio		 -84.91% -231.67% 366.24% 188.13% -478.66% 362.76% -1.36% -1.38% -1.41% -1.39% -175.68%

Financials Breakdown Chart

Key Financial Trends

Mesa Laboratories (NASDAQ: MLAB) showed a sharp recovery in profitability in fiscal 2025, but the business is still dealing with a highly leveraged balance sheet and uneven cash flow. Over the last several quarters, revenue has generally been stable to slightly higher, operating margins improved meaningfully in 2025, and debt has been reduced. However, the company remains burdened by large goodwill and intangible assets from prior acquisitions, and quarterly results can still swing between profit and loss.

  • Profitability improved dramatically in 2025. After posting a large loss in Q4 2024, Mesa Laboratories returned to profitability in Q1 and Q2 2025, and Q3 2025 was solidly profitable with net income of $3.6 million.
  • Operating income rebounded. Q3 2025 operating income was $8.0 million, compared with a small loss in Q2 2025 and a loss in Q4 2024, showing better cost control and margin recovery.
  • Revenue has held relatively steady. Quarterly revenue has stayed in the roughly $53 million to $65 million range over the past year, with Q4 2025 revenue at $59.8 million.
  • Debt has come down versus prior periods. Long-term debt fell to $161.0 million in Q3 2025 from $170.2 million in Q2 2025 and $232.9 million in Q3 2024, suggesting management has continued deleveraging.
  • Operating cash flow was strong in Q3 2025. The company generated $18.4 million in cash from operations, which is a healthy sign after weaker periods earlier in the year.
  • Cash and equivalents improved into Q3 2025. Cash rose to $28.0 million at the end of Q3 2025 from $20.4 million in Q2 2025.
  • Gross profit remained resilient. Gross profit has generally stayed in the low-to-mid $30 million range per quarter, which indicates the company still has decent underlying product profitability.
  • Capital spending has been modest. Quarterly purchases of property, plant and equipment have been relatively small, generally around $0.5 million to $1.8 million, so the company is not currently in a heavy investment cycle.
  • Q4 2025 was a weak quarter on the bottom line. Mesa posted a net loss of $12.4 million, reversing the prior quarter’s profit.
  • Q4 2025 operating cash flow turned negative. Net cash from operating activities was reported at negative $6.1 million, a deterioration from positive operating cash flow in Q3 2025.
  • Financing cash outflows remain large. The company repaid $17.1 million of debt in Q4 2025 and has continued paying dividends, which reduces financial flexibility.
  • Balance sheet quality is still a concern. Goodwill and intangible assets remain very large relative to total assets, reflecting a history of acquisitions and potential future impairment risk.

Bottom line: Mesa Laboratories appears to be in a turnaround phase with better operating profitability and some debt reduction, but investors should watch for volatility in quarterly earnings and cash flow. The company’s leverage and acquisition-related intangible assets still make the story riskier than a typical steady industrial or medical device name.

07/05/26 09:18 AM ETAI Generated. May Contain Errors.

Mesa Laboratories Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Mesa Laboratories' fiscal year ends in March. Their fiscal year 2026 ended on March 31, 2026.

Mesa Laboratories' net income appears to be on an upward trend, with a most recent value of $6.71 million in 2026, falling from $11.17 million in 2016. The previous period was -$1.97 million in 2025. See where experts think Mesa Laboratories is headed by visiting Mesa Laboratories' forecast page.

Mesa Laboratories' total operating income in 2026 was $18.51 million, based on the following breakdown:
  • Total Gross Profit: $158.27 million
  • Total Operating Expenses: $139.76 million

Over the last 10 years, Mesa Laboratories' total revenue changed from $169.32 million in 2016 to $249.13 million in 2026, a change of 47.1%.

Mesa Laboratories' total liabilities were at $241.50 million at the end of 2026, a 11.7% decrease from 2025, and a 217.5% increase since 2016.

In the past 10 years, Mesa Laboratories' cash and equivalents has ranged from $5.47 million in 2018 to $263.87 million in 2021, and is currently $26.93 million as of their latest financial filing in 2026.

Over the last 10 years, Mesa Laboratories' book value per share changed from 23.35 in 2016 to 33.71 in 2026, a change of 44.4%.


Related Companies

Financial statements for NASDAQ:MLAB last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel